BioScience Health Innovations I

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $0.6M normalized FCF base (approx. FY2025 net income of $642K on $5.69M revenue, up 208% YoY per 10-K); growth declining from 35% to 15% years 1-5, then 8% to 4% years 6-10; 20% discount rate (nano-cap OTC illiquidity/disclosure risk); 3% terminal growth; ~$0 net cash assumed (not disclosed); 11.75M shares outstanding.

Reasoning: This is a tiny, thinly-covered OTC nano-cap, so a high discount rate was used for illiquidity and limited-disclosure risk, and its recent triple-digit revenue growth was tapered toward sustainable rates since that pace cannot persist for a decade.